Drugs Made In America Acquisition DMAA Cash Flow Statement (2025-2026)

NASDAQ DMAA
$10.89 +0.00 (+0.00%)
At close: Oct 2, 2026 · 4:00 PM EDT
Reported Financials

Drugs Made In America Acquisition Quarterly Cash Flow Statement

Periods 5 quarters
Latest Jun 2026

Drugs Made In America Acquisition cash flow statement data for the quarter ended Jun 2026. This cash flow statement covers 5 quarters of results from Mar 2025 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Mar2025 Jun2025 Sep2025 Dec2025 Jun2026
Operating Activities
Net Income 1.25M2.29M2.18M0.21M1.73M
Cash from Operations -0.25M-0.11M-0.06M-0.13M
Change in Working Capital
Change in Accured Expenses 0.06M0.01M0.16M-0.08M
Other Working Capital Changes 0.07M-0.02M-0.02M-0.02M
Investing Activities
Cash from Investing Activities -231.15M
Financing Activities
Debt Issuance and Repayment
Long-Term Debt Repayments 0.90M
Change in Capital Stock
Net Equity Issued and Repurchased 3.20M
Misc.
Cash from Financing Activities 231.40M0.11M0.06M0.13M
Change in Cash -428.00-101.00-105.000.01M
Free Cash Flow -0.25M-0.11M-0.06M-0.13M
Net Cash Flow -428.00-101.00-105.000.01M

Drugs Made In America Acquisition Cash Flow Statement API

Pull Drugs Made In America Acquisition's standardized financial statements into your own models, spreadsheets and apps with the Business Quant Financial Statements API. The request below follows the statement, frequency and period selected above. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/statements?ticker=DMAA&statement=CF&frequency=Quarter&period=all&api_key=YOUR_API_KEY